| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 14 | 2025 | 191 | 2.750 |
Why?
|
| B7-H1 Antigen | 20 | 2025 | 305 | 2.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2025 | 1000 | 2.210 |
Why?
|
| NF-kappa B | 11 | 2016 | 408 | 1.640 |
Why?
|
| T-Lymphocytes | 15 | 2016 | 1276 | 1.530 |
Why?
|
| Albumins | 7 | 2021 | 123 | 1.130 |
Why?
|
| Paclitaxel | 8 | 2021 | 478 | 1.050 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2008 | 207 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 2543 | 0.980 |
Why?
|
| Graft Rejection | 10 | 2016 | 1123 | 0.870 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 537 | 0.820 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 223 | 0.750 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 555 | 0.750 |
Why?
|
| CARD Signaling Adaptor Proteins | 4 | 2012 | 15 | 0.710 |
Why?
|
| Antibodies, Monoclonal | 12 | 2019 | 1385 | 0.710 |
Why?
|
| Heart Transplantation | 6 | 2016 | 814 | 0.660 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2012 | 424 | 0.650 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 2301 | 0.610 |
Why?
|
| Lymphocyte Activation | 11 | 2016 | 798 | 0.600 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 795 | 0.580 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2014 | 339 | 0.540 |
Why?
|
| Biomarkers, Tumor | 11 | 2024 | 1660 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1447 | 0.500 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1980 | 0.450 |
Why?
|
| Cell Differentiation | 2 | 2012 | 1611 | 0.440 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 135 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2025 | 1130 | 0.420 |
Why?
|
| Interleukin-7 | 1 | 2014 | 47 | 0.410 |
Why?
|
| Bevacizumab | 4 | 2024 | 254 | 0.410 |
Why?
|
| Skin Transplantation | 3 | 2016 | 191 | 0.410 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 38 | 0.410 |
Why?
|
| Melanoma | 3 | 2019 | 494 | 0.400 |
Why?
|
| Signal Transduction | 9 | 2016 | 3497 | 0.400 |
Why?
|
| Mice, Inbred BALB C | 10 | 2016 | 1099 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 3431 | 0.390 |
Why?
|
| Genetic Variation | 1 | 2019 | 1416 | 0.380 |
Why?
|
| Th17 Cells | 2 | 2014 | 93 | 0.380 |
Why?
|
| Transplantation | 1 | 2012 | 38 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 174 | 0.350 |
Why?
|
| Mice | 20 | 2023 | 12230 | 0.350 |
Why?
|
| Female | 34 | 2025 | 48542 | 0.340 |
Why?
|
| Killer Cells, Natural | 3 | 2008 | 287 | 0.340 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 83 | 0.340 |
Why?
|
| Humans | 53 | 2025 | 93132 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 317 | 0.340 |
Why?
|
| Dendritic Cells | 2 | 2012 | 538 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 304 | 0.320 |
Why?
|
| Middle Aged | 25 | 2025 | 27535 | 0.320 |
Why?
|
| Galectin 1 | 2 | 2011 | 6 | 0.310 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 215 | 0.310 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 2363 | 0.300 |
Why?
|
| Transplantation, Homologous | 8 | 2016 | 1014 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 446 | 0.300 |
Why?
|
| Indoles | 2 | 2024 | 298 | 0.300 |
Why?
|
| Obesity | 1 | 2016 | 1014 | 0.290 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 1581 | 0.290 |
Why?
|
| Caspases | 1 | 2009 | 151 | 0.290 |
Why?
|
| fas Receptor | 1 | 2009 | 73 | 0.290 |
Why?
|
| CD28 Antigens | 4 | 2011 | 94 | 0.290 |
Why?
|
| Animals | 22 | 2023 | 27973 | 0.290 |
Why?
|
| Cytokines | 4 | 2019 | 862 | 0.280 |
Why?
|
| Skin | 3 | 2019 | 575 | 0.280 |
Why?
|
| Thymus Gland | 1 | 2009 | 196 | 0.270 |
Why?
|
| CD3 Complex | 3 | 2011 | 135 | 0.270 |
Why?
|
| STAT5 Transcription Factor | 3 | 2014 | 44 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2004 | 121 | 0.270 |
Why?
|
| Langerhans Cells | 1 | 2007 | 17 | 0.270 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2004 | 34 | 0.270 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2004 | 38 | 0.260 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 46 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1339 | 0.260 |
Why?
|
| Cell Cycle | 1 | 2009 | 515 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 191 | 0.250 |
Why?
|
| Mice, Knockout | 6 | 2012 | 2121 | 0.250 |
Why?
|
| Isoantigens | 3 | 2012 | 72 | 0.250 |
Why?
|
| Up-Regulation | 3 | 2004 | 727 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 87 | 0.250 |
Why?
|
| I-kappa B Kinase | 3 | 2016 | 41 | 0.240 |
Why?
|
| Automation | 2 | 2024 | 106 | 0.240 |
Why?
|
| Aged | 20 | 2025 | 20395 | 0.240 |
Why?
|
| Adult | 23 | 2025 | 27849 | 0.240 |
Why?
|
| MAP Kinase Signaling System | 2 | 2003 | 200 | 0.230 |
Why?
|
| Inflammation | 3 | 2016 | 1049 | 0.220 |
Why?
|
| src-Family Kinases | 1 | 2004 | 70 | 0.210 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 1060 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 663 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 76 | 0.200 |
Why?
|
| Immunophenotyping | 1 | 2024 | 224 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3814 | 0.190 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2003 | 3 | 0.190 |
Why?
|
| Ovalbumin | 2 | 2014 | 103 | 0.190 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 98 | 0.180 |
Why?
|
| Interleukin-2 | 3 | 2011 | 244 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2025 | 9070 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2023 | 276 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 304 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1786 | 0.170 |
Why?
|
| Kinetics | 3 | 2018 | 1463 | 0.170 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 173 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1727 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 48 | 0.160 |
Why?
|
| Cells, Cultured | 6 | 2011 | 2827 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 110 | 0.160 |
Why?
|
| Immunoassay | 1 | 2020 | 99 | 0.160 |
Why?
|
| Immunotherapy | 5 | 2024 | 762 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 157 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 7039 | 0.150 |
Why?
|
| Prognosis | 4 | 2020 | 3890 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 47 | 0.150 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 148 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 481 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 636 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2020 | 234 | 0.140 |
Why?
|
| Biomarkers | 3 | 2021 | 1905 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 391 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 129 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 810 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 305 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 3155 | 0.130 |
Why?
|
| Male | 14 | 2025 | 44355 | 0.130 |
Why?
|
| Graft Survival | 3 | 2016 | 939 | 0.130 |
Why?
|
| Apoptosis | 3 | 2011 | 1719 | 0.130 |
Why?
|
| Interferon-gamma | 2 | 2016 | 459 | 0.130 |
Why?
|
| Isoenzymes | 2 | 2008 | 271 | 0.130 |
Why?
|
| Protein Kinase C | 2 | 2008 | 260 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1908 | 0.130 |
Why?
|
| Azetidines | 1 | 2017 | 36 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 376 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1318 | 0.130 |
Why?
|
| Neoplasms | 3 | 2024 | 3168 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2020 | 700 | 0.120 |
Why?
|
| Alleles | 1 | 2019 | 1139 | 0.120 |
Why?
|
| Microfluidics | 1 | 2016 | 57 | 0.120 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 30 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 72 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 162 | 0.120 |
Why?
|
| Piperidines | 1 | 2017 | 163 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2018 | 280 | 0.120 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 2009 | 0.120 |
Why?
|
| Immune Tolerance | 3 | 2012 | 378 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1719 | 0.120 |
Why?
|
| Cell Survival | 3 | 2014 | 1002 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2011 | 710 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 2016 | 99 | 0.110 |
Why?
|
| Spleen | 1 | 2016 | 372 | 0.110 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 277 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1776 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2017 | 331 | 0.110 |
Why?
|
| Body Weight | 1 | 2016 | 449 | 0.110 |
Why?
|
| Drug Tolerance | 1 | 2014 | 59 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 30 | 0.110 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2014 | 9 | 0.110 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 30 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 2004 | 22 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 621 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 104 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 981 | 0.100 |
Why?
|
| Mice, Inbred C3H | 3 | 2012 | 368 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 159 | 0.100 |
Why?
|
| Heart | 1 | 2016 | 522 | 0.100 |
Why?
|
| Antigens | 1 | 2014 | 223 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Cross-Priming | 1 | 2012 | 54 | 0.090 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 2 | 2009 | 8 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 638 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 87 | 0.090 |
Why?
|
| beta Catenin | 1 | 2014 | 265 | 0.090 |
Why?
|
| Time Factors | 5 | 2019 | 5380 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2024 | 92 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1732 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 1114 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 866 | 0.090 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 215 | 0.090 |
Why?
|
| Liquid Biopsy | 2 | 2022 | 48 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 1071 | 0.090 |
Why?
|
| Multiprotein Complexes | 2 | 2009 | 106 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2484 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2012 | 260 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1769 | 0.080 |
Why?
|
| Colitis | 1 | 2014 | 260 | 0.080 |
Why?
|
| Microbiota | 1 | 2016 | 431 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2006 | 121 | 0.080 |
Why?
|
| Colon | 1 | 2014 | 540 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2757 | 0.080 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 37 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2011 | 184 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 660 | 0.080 |
Why?
|
| Peptides | 2 | 2011 | 653 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2009 | 203 | 0.080 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2012 | 247 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 825 | 0.080 |
Why?
|
| Mutation | 4 | 2023 | 4265 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 578 | 0.080 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2009 | 7 | 0.080 |
Why?
|
| Phenotype | 1 | 2016 | 2545 | 0.070 |
Why?
|
| Chromatin | 1 | 2012 | 440 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 6922 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 1171 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 47 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 47 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 346 | 0.070 |
Why?
|
| Survival Rate | 2 | 2025 | 1945 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 280 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 36 | 0.070 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 28 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2008 | 10 | 0.070 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 55 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2011 | 774 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 1529 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 37 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 238 | 0.070 |
Why?
|
| Epidermis | 1 | 2007 | 103 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 184 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1518 | 0.060 |
Why?
|
| Adolescent | 4 | 2021 | 9550 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 364 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 68 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 102 | 0.060 |
Why?
|
| Glioma | 1 | 2008 | 298 | 0.060 |
Why?
|
| Stem Cells | 1 | 2008 | 386 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2019 | 10128 | 0.060 |
Why?
|
| Lung Transplantation | 1 | 2010 | 367 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 216 | 0.060 |
Why?
|
| Butadienes | 1 | 2004 | 33 | 0.050 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 34 | 0.050 |
Why?
|
| Superantigens | 1 | 2004 | 24 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2012 | 1687 | 0.050 |
Why?
|
| Nitriles | 1 | 2004 | 154 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 113 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2479 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 138 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2020 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 3044 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1909 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 208 | 0.050 |
Why?
|
| Sirolimus | 1 | 2004 | 176 | 0.050 |
Why?
|
| Calcineurin | 1 | 2003 | 19 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 1304 | 0.050 |
Why?
|
| Pyridines | 1 | 2004 | 302 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 94 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 196 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 288 | 0.050 |
Why?
|
| DNA Probes | 1 | 2002 | 66 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 58 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 43 | 0.050 |
Why?
|
| Ribose | 1 | 2022 | 20 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 58 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2023 | 143 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 56 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 64 | 0.040 |
Why?
|
| Heterozygote | 1 | 2002 | 381 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 885 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 279 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 393 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 290 | 0.040 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2020 | 4 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2020 | 29 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2021 | 86 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 52 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 126 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 106 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 109 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 245 | 0.040 |
Why?
|
| Binding Sites | 2 | 2014 | 1126 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 321 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 287 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 278 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 154 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 283 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 30 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 258 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 688 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1172 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 195 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 10 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 80 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 27 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 89 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2011 | 74 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 121 | 0.030 |
Why?
|
| Fatigue | 1 | 2019 | 181 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 63 | 0.030 |
Why?
|
| Protein Kinase C-theta | 2 | 2008 | 16 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2011 | 281 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 319 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 61 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 338 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 400 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 570 | 0.030 |
Why?
|
| Models, Biological | 1 | 2004 | 1768 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 412 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 188 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2018 | 179 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 357 | 0.030 |
Why?
|
| CD40 Ligand | 2 | 2008 | 77 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 848 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 555 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 39 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 877 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 277 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 51 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 77 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2008 | 476 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 531 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7581 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 146 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 116 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 171 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 173 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 205 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 210 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 888 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 321 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 647 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 152 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 19 | 0.030 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 25 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2014 | 80 | 0.030 |
Why?
|
| Sulfasalazine | 2 | 2004 | 33 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 528 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 762 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 79 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 367 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1910 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 296 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 103 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 655 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 883 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2016 | 295 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 465 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2004 | 517 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1120 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 773 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 456 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 66 | 0.020 |
Why?
|
| Protein Binding | 2 | 2004 | 1526 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 833 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 143 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 10 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2008 | 73 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 54 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 33 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1231 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 774 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2008 | 144 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 52 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2008 | 122 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 399 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 216 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 201 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 281 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2006 | 46 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 672 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 823 | 0.020 |
Why?
|
| Ionomycin | 1 | 2006 | 19 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2006 | 36 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 35 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 46 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1703 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 139 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2006 | 276 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2006 | 166 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2006 | 150 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 958 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2008 | 443 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 210 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 43 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 556 | 0.010 |
Why?
|
| Dimerization | 1 | 2004 | 148 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 273 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 135 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 577 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 298 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 523 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 12 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 2002 | 21 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2002 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2002 | 21 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 39 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1994 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 2889 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1353 | 0.010 |
Why?
|